BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30266801)

  • 1. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
    Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
    Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
    Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
    Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators.
    Vachtenheim J; Sestáková B; Tuhácková Z
    Pigment Cell Res; 2007 Feb; 20(1):41-51. PubMed ID: 17250547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300.
    Brown AD; Lynch K; Langelaan DN
    Sci Rep; 2023 Sep; 13(1):16094. PubMed ID: 37752231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPTF transduces MITF-driven prosurvival signals in melanoma cells.
    Dar AA; Majid S; Bezrookove V; Phan B; Ursu S; Nosrati M; De Semir D; Sagebiel RW; Miller JR; Debs R; Cleaver JE; Kashani-Sabet M
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6254-8. PubMed ID: 27185926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes.
    Bandyopadhyay D; Okan NA; Bales E; Nascimento L; Cole PA; Medrano EE
    Cancer Res; 2002 Nov; 62(21):6231-9. PubMed ID: 12414652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene.
    Saladi SV; Wong PG; Trivedi AR; Marathe HG; Keenen B; Aras S; Liew ZQ; Setaluri V; de la Serna IL
    Pigment Cell Melanoma Res; 2013 May; 26(3):377-91. PubMed ID: 23480510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
    Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
    J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
    Yokoyama S; Feige E; Poling LL; Levy C; Widlund HR; Khaled M; Kung AL; Fisher DE
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):457-63. PubMed ID: 18627530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylation reprograms MITF target selectivity and residence time.
    Louphrasitthiphol P; Loffreda A; Pogenberg V; Picaud S; Schepsky A; Friedrichsen H; Zeng Z; Lashgari A; Thomas B; Patton EE; Wilmanns M; Filippakopoulos P; Lambert JP; Steingrímsson E; Mazza D; Goding CR
    Nat Commun; 2023 Sep; 14(1):6051. PubMed ID: 37770430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas.
    Giuliano S; Cheli Y; Ohanna M; Bonet C; Beuret L; Bille K; Loubat A; Hofman V; Hofman P; Ponzio G; Bahadoran P; Ballotti R; Bertolotto C
    Cancer Res; 2010 May; 70(9):3813-22. PubMed ID: 20388797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation.
    Wong CK; Wade-Vallance AK; Luciani DS; Brindle PK; Lynn FC; Gibson WT
    Diabetes; 2018 Mar; 67(3):412-422. PubMed ID: 29217654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
    Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B
    Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.
    Javelaud D; Alexaki VI; Pierrat MJ; Hoek KS; Dennler S; Van Kempen L; Bertolotto C; Ballotti R; Saule S; Delmas V; Mauviel A
    Pigment Cell Melanoma Res; 2011 Oct; 24(5):932-43. PubMed ID: 21801332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
    Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
    Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.
    Kramer D; Schön M; Bayerlová M; Bleckmann A; Schön MP; Zörnig M; Dobbelstein M
    Cell Death Dis; 2015 Feb; 6(2):e1634. PubMed ID: 25675294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
    Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
    J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression.
    He S; Li CG; Slobbe L; Glover A; Marshall E; Baguley BC; Eccles MR
    Melanoma Res; 2011 Feb; 21(1):24-34. PubMed ID: 21164369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.